MedTrace Logo

Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal Photocoagulation

NCT00801905 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-05-30

No results posted yet for this study

Summary

The purpose of this study is to determine whether topical nepafenac (qid) is effective in preventing and treating macular thickening related pan-retinal photocoagulation in patients with diabetic retinopathy.

Conditions

  • Macular Thickening
  • Macular Edema

Interventions

DRUG

Nepafenac

Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.

OTHER

Lubricant

Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed

Sponsors & Collaborators

  • Asociación para Evitar la Ceguera en México

    lead OTHER

Principal Investigators

  • Dulce O Rascon-Vargas, Fellow · Asociación Para Evitar la Ceguera en México I.A.P.

  • Guadalupe Cervantes-Coste · Asociación Para Evitar la Ceguera en México I.A.P.

  • Jans Fromow-Guerra · Asociación Para Evitar la Ceguera en México I.A.P.

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2008-12-31
Completion
2009-03-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00801905 on ClinicalTrials.gov